174 related articles for article (PubMed ID: 36219674)
1. On the Recognition of Natural Substrate CTP and Endogenous Inhibitor ddhCTP of SARS-CoV-2 RNA-Dependent RNA Polymerase: A Molecular Dynamics Study.
Parise A; Ciardullo G; Prejanò M; Lande A; Marino T
J Chem Inf Model; 2022 Oct; 62(20):4916-4927. PubMed ID: 36219674
[TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 nsp14 Exoribonuclease Removes the Natural Antiviral 3'-Deoxy-3',4'-didehydro-cytidine Nucleotide from RNA.
Moeller NH; Passow KT; Harki DA; Aihara H
Viruses; 2022 Aug; 14(8):. PubMed ID: 36016411
[TBL] [Abstract][Full Text] [Related]
3. Structural Basis of the Potential Binding Mechanism of Remdesivir to SARS-CoV-2 RNA-Dependent RNA Polymerase.
Zhang L; Zhou R
J Phys Chem B; 2020 Aug; 124(32):6955-6962. PubMed ID: 32521159
[TBL] [Abstract][Full Text] [Related]
4. Plant-Derived Natural Non-Nucleoside Analog Inhibitors (NNAIs) against
Naidu SAG; Mustafa G; Clemens RA; Naidu AS
J Diet Suppl; 2023; 20(2):254-283. PubMed ID: 34850656
[TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2 RdRp uses NDPs as a substrate and is able to incorporate NHC into RNA from diphosphate form molnupiravir.
Wang M; Wu C; Liu N; Zhang F; Dong H; Wang S; Chen M; Jiang X; Zhang K; Gu L
Int J Biol Macromol; 2023 Jan; 226():946-955. PubMed ID: 36528144
[TBL] [Abstract][Full Text] [Related]
6. A dual mechanism of action of AT-527 against SARS-CoV-2 polymerase.
Shannon A; Fattorini V; Sama B; Selisko B; Feracci M; Falcou C; Gauffre P; El Kazzi P; Delpal A; Decroly E; Alvarez K; Eydoux C; Guillemot JC; Moussa A; Good SS; La Colla P; Lin K; Sommadossi JP; Zhu Y; Yan X; Shi H; Ferron F; Canard B
Nat Commun; 2022 Feb; 13(1):621. PubMed ID: 35110538
[TBL] [Abstract][Full Text] [Related]
7. Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase, a Key Drug Target for COVID-19.
Chien M; Anderson TK; Jockusch S; Tao C; Li X; Kumar S; Russo JJ; Kirchdoerfer RN; Ju J
J Proteome Res; 2020 Nov; 19(11):4690-4697. PubMed ID: 32692185
[TBL] [Abstract][Full Text] [Related]
8. Targeting the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) with synthetic/designer unnatural nucleoside analogs: an in silico study.
Bag SS; Sinha S; Dutta S; Baishya HJ; Paul S
J Mol Model; 2023 Nov; 29(12):366. PubMed ID: 37950101
[TBL] [Abstract][Full Text] [Related]
9. RNA-dependent RNA polymerase of SARS-CoV-2 as a therapeutic target.
Wang Y; Anirudhan V; Du R; Cui Q; Rong L
J Med Virol; 2021 Jan; 93(1):300-310. PubMed ID: 32633831
[TBL] [Abstract][Full Text] [Related]
10. Biostructural Models for the Binding of Nucleoside Analogs to SARS-CoV-2 RNA-Dependent RNA Polymerase.
Prussia AJ; Chennamadhavuni S
J Chem Inf Model; 2021 Mar; 61(3):1402-1411. PubMed ID: 33655751
[TBL] [Abstract][Full Text] [Related]
11. Chemical Synthesis of the Antiviral Nucleotide Analogue ddhCTP.
Wood JM; Evans GB; Grove TL; Almo SC; Cameron SA; Furneaux RH; Harris LD
J Org Chem; 2021 Jul; 86(13):8843-8850. PubMed ID: 34126010
[TBL] [Abstract][Full Text] [Related]
12. State-of-the-Art Molecular Dynamics Simulation Studies of RNA-Dependent RNA Polymerase of SARS-CoV-2.
Tanimoto S; Itoh SG; Okumura H
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142270
[TBL] [Abstract][Full Text] [Related]
13. Mechanistic insight on the remdesivir binding to RNA-Dependent RNA polymerase (RdRp) of SARS-cov-2.
Arba M; Wahyudi ST; Brunt DJ; Paradis N; Wu C
Comput Biol Med; 2021 Feb; 129():104156. PubMed ID: 33260103
[TBL] [Abstract][Full Text] [Related]
14. Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir.
Yin W; Mao C; Luan X; Shen DD; Shen Q; Su H; Wang X; Zhou F; Zhao W; Gao M; Chang S; Xie YC; Tian G; Jiang HW; Tao SC; Shen J; Jiang Y; Jiang H; Xu Y; Zhang S; Zhang Y; Xu HE
Science; 2020 Jun; 368(6498):1499-1504. PubMed ID: 32358203
[TBL] [Abstract][Full Text] [Related]
15. A computational approach to drug repurposing against SARS-CoV-2 RNA dependent RNA polymerase (RdRp).
Ribaudo G; Ongaro A; Oselladore E; Zagotto G; Memo M; Gianoncelli A
J Biomol Struct Dyn; 2022 Feb; 40(3):1101-1108. PubMed ID: 32948103
[TBL] [Abstract][Full Text] [Related]
16. Structural basis for backtracking by the SARS-CoV-2 replication-transcription complex.
Malone B; Chen J; Wang Q; Llewellyn E; Choi YJ; Olinares PDB; Cao X; Hernandez C; Eng ET; Chait BT; Shaw DE; Landick R; Darst SA; Campbell EA
Proc Natl Acad Sci U S A; 2021 May; 118(19):. PubMed ID: 33883267
[TBL] [Abstract][Full Text] [Related]
17. Viral RNA Replication Suppression of SARS-CoV-2: Atomistic Insights into Inhibition Mechanisms of RdRp Machinery by ddhCTP.
Ciardullo G; Parise A; Prejanò M; Marino T
J Chem Inf Model; 2024 Mar; 64(5):1593-1604. PubMed ID: 38412057
[TBL] [Abstract][Full Text] [Related]
18. A naturally occurring antiviral ribonucleotide encoded by the human genome.
Gizzi AS; Grove TL; Arnold JJ; Jose J; Jangra RK; Garforth SJ; Du Q; Cahill SM; Dulyaninova NG; Love JD; Chandran K; Bresnick AR; Cameron CE; Almo SC
Nature; 2018 Jun; 558(7711):610-614. PubMed ID: 29925952
[TBL] [Abstract][Full Text] [Related]
19. Sangivamycin is preferentially incorporated into viral RNA by the SARS-CoV-2 polymerase.
Bennett RP; Yoluç Y; Salter JD; Ripp A; Jessen HJ; Kaiser SM; Smith HC
Antiviral Res; 2023 Oct; 218():105716. PubMed ID: 37690700
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of action of T-705 ribosyl triphosphate against influenza virus RNA polymerase.
Sangawa H; Komeno T; Nishikawa H; Yoshida A; Takahashi K; Nomura N; Furuta Y
Antimicrob Agents Chemother; 2013 Nov; 57(11):5202-8. PubMed ID: 23917318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
